Clinical Trials · NCT03289741
A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Enrollment
- 51
- Start date
- Sep 2017
- Locations
- 7 sites, United States
- Primary endpoint
- Mean Pain Scores at 3 Months